Adam Scott Levy Sells 96,815 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 96,815 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $12.94, for a total value of $1,252,786.10. Following the completion of the transaction, the chief financial officer now directly owns 255,462 shares in the company, valued at approximately $3,305,678.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mineralys Therapeutics Stock Up 0.7 %

Shares of NASDAQ:MLYS traded up $0.09 during midday trading on Thursday, hitting $12.69. The stock had a trading volume of 163,210 shares, compared to its average volume of 154,603. The company has a market capitalization of $630.05 million, a P/E ratio of -5.75 and a beta of 2.03. The company’s 50-day moving average price is $12.70 and its 200-day moving average price is $11.61. Mineralys Therapeutics, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $17.44.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.02). Research analysts expect that Mineralys Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Analysts Set New Price Targets

MLYS has been the subject of a number of research reports. The Goldman Sachs Group assumed coverage on Mineralys Therapeutics in a report on Tuesday, April 2nd. They set a “buy” rating and a $30.00 target price for the company. Lifesci Capital reiterated an “outperform” rating on shares of Mineralys Therapeutics in a research note on Tuesday, March 26th.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. boosted its stake in Mineralys Therapeutics by 17,821.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock valued at $35,000 after buying an additional 4,099 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Mineralys Therapeutics in the fourth quarter worth about $41,000. CWM LLC boosted its stake in shares of Mineralys Therapeutics by 120.0% in the 4th quarter. CWM LLC now owns 5,891 shares of the company’s stock valued at $51,000 after purchasing an additional 3,213 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Mineralys Therapeutics during the 4th quarter valued at approximately $87,000. Finally, CreativeOne Wealth LLC acquired a new position in Mineralys Therapeutics during the 4th quarter worth approximately $92,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.